325 related articles for article (PubMed ID: 25866054)
1. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
[TBL] [Abstract][Full Text] [Related]
2. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
Luo X; Peng X; Hou J; Wu S; Shen J; Wang L
Int J Nanomedicine; 2017; 12():5331-5343. PubMed ID: 28794626
[TBL] [Abstract][Full Text] [Related]
3. A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
Wen J; Qiu N; Zhu Z; Bai P; Hu M; Qi W; Liu Y; Wei A; Chen L
Drug Deliv; 2021 Dec; 28(1):1055-1066. PubMed ID: 34078185
[TBL] [Abstract][Full Text] [Related]
4. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
[TBL] [Abstract][Full Text] [Related]
5. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
[TBL] [Abstract][Full Text] [Related]
6. Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.
Jones SK; Lizzio V; Merkel OM
Biomacromolecules; 2016 Jan; 17(1):76-87. PubMed ID: 26636884
[TBL] [Abstract][Full Text] [Related]
7. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
8. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.
Cubillos-Ruiz JR; Engle X; Scarlett UK; Martinez D; Barber A; Elgueta R; Wang L; Nesbeth Y; Durant Y; Gewirtz AT; Sentman CL; Kedl R; Conejo-Garcia JR
J Clin Invest; 2009 Aug; 119(8):2231-44. PubMed ID: 19620771
[TBL] [Abstract][Full Text] [Related]
9. Non-covalent Nanocomplexes of Folic Acid and Reducible Polyethylenimine for Survivin siRNA Delivery.
Zheng B; Yang S; Wang M; Yang X; Teng L; Xie J; Teng L; Lee RJ
Anticancer Res; 2015 Oct; 35(10):5433-41. PubMed ID: 26408706
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
12. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
13. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the value of competition assays in folate receptor-mediated drug delivery.
Jones SK; Sarkar A; Feldmann DP; Hoffmann P; Merkel OM
Biomaterials; 2017 Sep; 138():35-45. PubMed ID: 28551461
[TBL] [Abstract][Full Text] [Related]
16. Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer.
Feldmann DP; Jones S; Douglas K; Shields AF; Merkel OM
Methods Mol Biol; 2019; 1974():355-369. PubMed ID: 31099014
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG
Man RCH; Qiu Y; Leung SWS; Fruhwirth GO; Lam JKW
Eur J Pharm Biopharm; 2024 Feb; 195():114177. PubMed ID: 38185193
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy.
Lv H; Wang T; Ma F; Zhang K; Gao T; Pei R; Zhang Y
Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147520
[TBL] [Abstract][Full Text] [Related]
20. IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
Carbotti G; Barisione G; Airoldi I; Mezzanzanica D; Bagnoli M; Ferrero S; Petretto A; Fabbi M; Ferrini S
Oncotarget; 2015 Dec; 6(41):43267-80. PubMed ID: 26657115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
